sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
|
EDECRIN
|
diuretic
|
NONE
|
Ethacrynic acid_ddi.xml
|
DDI-DrugBank.d414.s7
|
DDI-DrugBank.d414.s7.p1
|
only ibogaine enhances cocaine-induced increases in accumbal dopamine.
|
ibogaine
|
cocaine
|
EFFECT
|
11085336.xml
|
DDI-MedLine.d110.s7
|
DDI-MedLine.d110.s7.p0
|
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
|
triazolam
|
Aprepitant
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s23
|
DDI-DrugBank.d382.s23.p9
|
Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.
|
Histamine H2 antagonists
|
Cimetidine
|
MECHANISM
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s14
|
DDI-DrugBank.d143.s14.p0
|
Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.
|
Cimetidine
|
altretamine
|
MECHANISM
|
Altretamine_ddi.xml
|
DDI-DrugBank.d188.s0
|
DDI-DrugBank.d188.s0.p5
|
In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam.
|
entacapone
|
diazepam
|
NONE
|
Entacapone_ddi.xml
|
DDI-DrugBank.d455.s4
|
DDI-DrugBank.d455.s4.p3
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
bupropion
|
valproate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p211
|
Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.
|
ketoconazole
|
valdecoxib
|
NONE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s28
|
DDI-DrugBank.d328.s28.p4
|
Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone.
|
Bile acid binding resins
|
hydrocortisone
|
MECHANISM
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s17
|
DDI-DrugBank.d345.s17.p1
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
serotoninergic agents
|
fluvoxamine
|
NONE
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p22
|
With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
|
Vardenafil
|
terazosin
|
EFFECT
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s30
|
DDI-DrugBank.d198.s30.p0
|
Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).
|
Ibandronate
|
antacids
|
ADVISE
|
Ibandronate_ddi.xml
|
DDI-DrugBank.d440.s2
|
DDI-DrugBank.d440.s2.p0
|
Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L.
|
Acetaminophen
|
theophylline
|
MECHANISM
|
11206047.xml
|
DDI-MedLine.d111.s9
|
DDI-MedLine.d111.s9.p0
|
Oral Contraceptives Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.
|
Contraceptives
|
cefditoren pivoxil
|
NONE
|
Cefditoren_ddi.xml
|
DDI-DrugBank.d550.s0
|
DDI-DrugBank.d550.s0.p0
|
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
|
benzodiazepines
|
anticonvulsants
|
EFFECT
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s1
|
DDI-DrugBank.d338.s1.p0
|
Fluconazole, and the 5-HT3 antiemetics ondansetron (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.
|
5-HT3 antiemetics
|
BUSULFEX
|
NONE
|
Busulfan_ddi.xml
|
DDI-DrugBank.d72.s1
|
DDI-DrugBank.d72.s1.p10
|
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
|
Dexamethasone
|
insulin
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s0
|
DDI-MedLine.d12.s0.p2
|
Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone.
|
TAM
|
1,25(OH)2D3
|
EFFECT
|
7654327.xml
|
DDI-MedLine.d53.s4
|
DDI-MedLine.d53.s4.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
cimetidine
|
miconazole
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p557
|
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
|
Cholestyramine
|
tetracycline
|
MECHANISM
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s0
|
DDI-DrugBank.d566.s0.p5
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Nizoral
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p14
|
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
|
estazolam
|
carbamazepine
|
MECHANISM
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s4
|
DDI-DrugBank.d338.s4.p0
|
N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine.
|
N-methyllevallorphan
|
morphine
|
EFFECT
|
7625885.xml
|
DDI-MedLine.d128.s15
|
DDI-MedLine.d128.s15.p1
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
anticholinergic
|
antiarrhythmics
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p6
|
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
|
Dexamethasone
|
EGF
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s0
|
DDI-MedLine.d12.s0.p1
|
Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).
|
Vardenafil
|
aspirin
|
NONE
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s40
|
DDI-DrugBank.d198.s40.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Crixivan
|
temazepam
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p833
|
It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.
|
triamterene
|
INDOCIN
|
EFFECT
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s28
|
DDI-DrugBank.d82.s28.p0
|
In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.
|
non- steroidal antiinflammatory agent
|
loop diuretics
|
EFFECT
|
Ethacrynic acid_ddi.xml
|
DDI-DrugBank.d414.s6
|
DDI-DrugBank.d414.s6.p0
|
Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide
|
lithium
|
chlorothiazide
|
ADVISE
|
Chlorothiazide_ddi.xml
|
DDI-DrugBank.d46.s17
|
DDI-DrugBank.d46.s17.p0
|
Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
|
ZYVOX
|
serotonergic agents
|
EFFECT
|
Linezolid_ddi.xml
|
DDI-DrugBank.d441.s6
|
DDI-DrugBank.d441.s6.p0
|
The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.
|
cyclophosphamide
|
phenobarbital
|
MECHANISM
|
Cyclophosphamide_ddi.xml
|
DDI-DrugBank.d7.s0
|
DDI-DrugBank.d7.s0.p0
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
clarithromycin
|
telithromycin
|
NONE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p42
|
Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.
|
Anagrelide
|
theophylline
|
MECHANISM
|
Anagrelide_ddi.xml
|
DDI-DrugBank.d75.s12
|
DDI-DrugBank.d75.s12.p0
|
Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.
|
barbiturates
|
chlorpropamide
|
EFFECT
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s7
|
DDI-DrugBank.d245.s7.p0
|
Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.
|
Diflunisal
|
hydrochlorothiazide
|
EFFECT
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s6
|
DDI-DrugBank.d132.s6.p0
|
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
|
tricyclic antidepressants
|
cimetidine
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s6
|
DDI-DrugBank.d238.s6.p1
|
Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.
|
multivalent cations
|
alendronate
|
MECHANISM
|
Alendronate_ddi.xml
|
DDI-DrugBank.d430.s3
|
DDI-DrugBank.d430.s3.p2
|
Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
|
live vaccines
|
inactivated vaccines
|
NONE
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s30
|
DDI-DrugBank.d314.s30.p5
|
Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
|
opioids
|
INAPSINE
|
EFFECT
|
Droperidol_ddi.xml
|
DDI-DrugBank.d254.s0
|
DDI-DrugBank.d254.s0.p13
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
tolbutamide
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p49
|
Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.
|
Phenylbutazone
|
etodolac
|
MECHANISM
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s19
|
DDI-DrugBank.d219.s19.p2
|
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
fluoxetine
|
fluvoxamine
|
NONE
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s6
|
DDI-DrugBank.d299.s6.p18
|
There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.
|
antidepressants
|
fluoxetine hydrochloride
|
MECHANISM
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s6
|
DDI-DrugBank.d202.s6.p1
|
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
|
benzodiazepines
|
nicardipine
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s10
|
DDI-DrugBank.d131.s10.p4
|
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
|
carbamazepine
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s30
|
DDI-DrugBank.d124.s30.p9
|
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
|
guanethidine
|
amphetamines
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s0
|
DDI-DrugBank.d236.s0.p14
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Tegretol
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p8
|
Warfarin-Vitamin K can antagonize the effect of warfarin
|
Warfarin
|
warfarin
|
NONE
|
Menadione_ddi.xml
|
DDI-DrugBank.d139.s8
|
DDI-DrugBank.d139.s8.p1
|
In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
|
Angiomax
|
warfarin
|
EFFECT
|
Bivalirudin_ddi.xml
|
DDI-DrugBank.d569.s1
|
DDI-DrugBank.d569.s1.p1
|
Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).
|
tamoxifen
|
anastrozole
|
ADVISE
|
Anastrozole_ddi.xml
|
DDI-DrugBank.d195.s7
|
DDI-DrugBank.d195.s7.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
colistin
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p8
|
There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
|
dobutamine
|
lidocaine
|
NONE
|
Dobutamine_ddi.xml
|
DDI-DrugBank.d274.s3
|
DDI-DrugBank.d274.s3.p3
|
If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.
|
TARCEVA
|
rifampicin
|
ADVISE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s5
|
DDI-DrugBank.d456.s5.p0
|
Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.
|
HMG-CoA reductase inhibitors
|
immunosuppressive drugs
|
EFFECT
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s17
|
DDI-DrugBank.d165.s17.p0
|
Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.
|
PEGASYS
|
theophylline
|
MECHANISM
|
Peginterferon alfa-2a_ddi.xml
|
DDI-DrugBank.d196.s0
|
DDI-DrugBank.d196.s0.p0
|
Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.
|
colestipol
|
vitamin K
|
MECHANISM
|
Menadione_ddi.xml
|
DDI-DrugBank.d139.s4
|
DDI-DrugBank.d139.s4.p3
|
Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated digoxin concentrations.
|
azithromycin
|
Digoxin
|
NONE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s13
|
DDI-DrugBank.d53.s13.p0
|
Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.
|
thiazide diuretics
|
dihydrotachysterol
|
EFFECT
|
Dihydrotachysterol_ddi.xml
|
DDI-DrugBank.d452.s0
|
DDI-DrugBank.d452.s0.p0
|
Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.
|
cephalexin
|
probenecid
|
MECHANISM
|
Cephalexin_ddi.xml
|
DDI-DrugBank.d303.s4
|
DDI-DrugBank.d303.s4.p5
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
TARCEVA
|
ritonavir
|
ADVISE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p7
|
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.
|
STRATTERA
|
fluoxetine
|
ADVISE
|
Atomoxetine_ddi.xml
|
DDI-DrugBank.d11.s3
|
DDI-DrugBank.d11.s3.p1
|
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
|
Tagamet
|
phenytoin
|
MECHANISM
|
Cimetidine_ddi.xml
|
DDI-DrugBank.d171.s0
|
DDI-DrugBank.d171.s0.p1
|
Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.
|
efavirenz
|
azithromycin
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s8
|
DDI-DrugBank.d53.s8.p1
|
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
|
Antizol
|
ketoconazole
|
MECHANISM
|
Fomepizole_ddi.xml
|
DDI-DrugBank.d228.s2
|
DDI-DrugBank.d228.s2.p3
|
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
|
levobupivacaine
|
phenytoin
|
MECHANISM
|
Levobupivacaine_ddi.xml
|
DDI-DrugBank.d320.s3
|
DDI-DrugBank.d320.s3.p0
|
When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.
|
Bezalip
|
anticoagulants of the coumarin type
|
NONE
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s0
|
DDI-DrugBank.d291.s0.p3
|
Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
|
haloperidol
|
dopamine
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s7
|
DDI-DrugBank.d325.s7.p4
|
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
|
benzodiazepines
|
MAO inhibitors
|
EFFECT
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s1
|
DDI-DrugBank.d18.s1.p11
|
To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.
|
indinavir
|
VIDEX
|
ADVISE
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s15
|
DDI-DrugBank.d43.s15.p2
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
macrolide antibiotics
|
TIKOSYN
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p10
|
Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.
|
Argatroban
|
anticoagulants
|
EFFECT
|
Argatroban_ddi.xml
|
DDI-DrugBank.d148.s6
|
DDI-DrugBank.d148.s6.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
diflunisal
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p16
|
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).
|
captopril
|
diuretic
|
EFFECT
|
Captopril_ddi.xml
|
DDI-DrugBank.d175.s1
|
DDI-DrugBank.d175.s1.p0
|
ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.
|
ALLEGRA
|
aluminum
|
ADVISE
|
Fexofenadine_ddi.xml
|
DDI-DrugBank.d466.s20
|
DDI-DrugBank.d466.s20.p0
|
Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.
|
Cimetidine
|
tiagabine
|
NONE
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s15
|
DDI-DrugBank.d277.s15.p6
|
Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
|
PLETAL
|
omeprazole
|
ADVISE
|
Cilostazol_ddi.xml
|
DDI-DrugBank.d358.s0
|
DDI-DrugBank.d358.s0.p6
|
Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
|
EQUETROTM
|
Phenytoin
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s13
|
DDI-DrugBank.d94.s13.p6
|
Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.
|
timolol
|
guanfacine
|
EFFECT
|
Guanfacine_ddi.xml
|
DDI-DrugBank.d507.s5
|
DDI-DrugBank.d507.s5.p5
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
salicylate
|
Magan
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p30
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
nalidixic acid
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p31
|
Oral Hypoglycemics: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic agents.
|
insulin
|
hypoglycemic agents
|
NONE
|
Bepridil_ddi.xml
|
DDI-DrugBank.d137.s7
|
DDI-DrugBank.d137.s7.p5
|
Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
|
valproic acid
|
ethosuximide
|
MECHANISM
|
Ethosuximide_ddi.xml
|
DDI-DrugBank.d205.s0
|
DDI-DrugBank.d205.s0.p20
|
Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.
|
antacids
|
anticholinergic agents
|
MECHANISM
|
Dicyclomine_ddi.xml
|
DDI-DrugBank.d543.s7
|
DDI-DrugBank.d543.s7.p0
|
Phenobarbital: Decreases aspirin effectiveness by enzyme induction.
|
Phenobarbital
|
aspirin
|
MECHANISM
|
Aspirin_ddi.xml
|
DDI-DrugBank.d443.s6
|
DDI-DrugBank.d443.s6.p0
|
Prior administration of succinylcholine has no clinically important effect on the neuromuscular blocking action of NUROMAX.
|
succinylcholine
|
NUROMAX
|
NONE
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s0
|
DDI-DrugBank.d267.s0.p0
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
aminosalicylic acid
|
NONE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p4
|
Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
|
eplerenone
|
fluconazole
|
MECHANISM
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s3
|
DDI-DrugBank.d20.s3.p3
|
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;
|
ibogaine
|
morphine
|
EFFECT
|
11085336.xml
|
DDI-MedLine.d110.s6
|
DDI-MedLine.d110.s6.p1
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
sertraline
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p6
|
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
|
ergotamine
|
nifedipine
|
NONE
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s10
|
DDI-DrugBank.d131.s10.p14
|
RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]).
|
Sildenafil
|
selective serotonin reuptake inhibitors
|
NONE
|
11219477.xml
|
DDI-MedLine.d42.s5
|
DDI-MedLine.d42.s5.p0
|
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
|
antipsychotic agents
|
CNS depressants
|
EFFECT
|
Haloperidol_ddi.xml
|
DDI-DrugBank.d186.s3
|
DDI-DrugBank.d186.s3.p1
|
When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.
|
BREVIBLOC
|
morphine
|
MECHANISM
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s6
|
DDI-DrugBank.d422.s6.p9
|
Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.
|
anastrozole
|
tamoxifen
|
MECHANISM
|
Anastrozole_ddi.xml
|
DDI-DrugBank.d195.s8
|
DDI-DrugBank.d195.s8.p0
|
Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.
|
caffeine
|
enoxacin
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s4
|
DDI-DrugBank.d395.s4.p2
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
erythromycin
|
bromocriptine
|
INT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p9
|
Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, tacrine, and zileuton).
|
amitriptyline
|
zileuton
|
NONE
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s30
|
DDI-DrugBank.d210.s30.p1
|
For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.
|
vitamin K antagonists
|
nilutamide
|
ADVISE
|
Nilutamide_ddi.xml
|
DDI-DrugBank.d177.s3
|
DDI-DrugBank.d177.s3.p0
|
Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, the tricyclic antidepressants, and clozapine.
|
dextromethorphan
|
tricyclic antidepressants
|
NONE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s26
|
DDI-DrugBank.d480.s26.p3
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.